newsfilter
← Latest News
GlobeNewswire·

Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium

WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting